Health Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Adverse Drug Reactions

Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile Preliminary Phase III Data Also Shows Signs of Efficacy, Safety and

in Most Severe Patient Population

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced top-line data from three separate Phase II trials involving its lead cholesterol management compound, AEGR-733, which is a microsomal triglyceride transfer protein (MTP) inhibitor. All three trials were designed to evaluate the efficacy, safety and tolerability of low doses of AEGR-733 alone and in combination with other lipid lowering agents such as Lipitor, Zetia and fenofibrate. The largest trial...

• View Other Issues of Health Business Week
  
• View Other NewsRx Publications